Differentiation-inducing and anti-proliferative activities of lupeol on canine melanoma cells
© Ogihara et al.; licensee Springer. 2014
Received: 3 March 2014
Accepted: 20 October 2014
Published: 25 October 2014
Canine melanoma is the most common oral malignant tumor reported in the field of veterinary medicine. We found that lupeol, a lupine triterpene, inhibited mouse melanoma cell growth in vitro and in vivo by inducing cell differentiation. In the present study, we examined the differentiation-inducing activities of lupeol on 4 canine melanoma cells in vitro and in vivo.
The induction of canine melanoma cell differentiation by lupeol was confirmed by evaluating some differentiation markers such as tyrosinase with real-time RT-PCR. Furthermore, we transplanted canine melanoma cells into a severe combined immunodeficiency mouse, and studied the anti-progressive effects of lupeol on tumor tissue.
The gene expression of microphthalmia-associated transcription factor, tyrosinase, and tyrosinase-related protein-2, which are markers of pigment cell differentiation, was induced in 4 canine oral malignant melanoma cells by lupeol, and the agent markedly inhibited tumor progression in canine melanoma-bearing mice.
KeywordsLupeol Canine melanoma Differentiation-inducing activity Cytostatic effect Nonsurgical treatment
Melanoma is the most aggressive form of skin cancer that is derived from activated or genetically altered epidermal melanocytes (Oliveria et al. 2001). Human malignant melanoma is a highly metastatic cancer that is markedly resistant to chemotherapy with dacarbazine or temozolomide. Canine melanoma is the most common oral malignant tumor reported in the field of veterinary medicine (Bergman, 2007). It was reported that treatment of carboplastin significantly affects dogs with malignant melanoma, and achieved a response rate at 28% (Rassnick et al. 2001).
Lupeol, a plant pentacyclic triterpene, was previously shown to have various biological activities, such as anti-inflammatory (Fernández et al. 2001a,[b]), anti-cancer (Saleem 2009), and anti-metabolic syndrome (Sasaki et al. 2008; Hata et al. 2008; Itoh et al. 2009) activities. We previously demonstrated that lupeol inhibited mouse melanoma cell growth by inducing melanogenesis and suppressing the motility of cells (Hata et al. 2006). These findings revealed that lupeol induced the differentiation of melanoma cells into mature melanocyte-like cells in vitro. In our recent study, we showed that lupeol suppressed tumor growth in melanoma-bearing mice by attenuating proliferating cell nuclear factor (PCNA) and Ki67, which are highly expressed in melanoma or other tumors (Nitta et al. 2013). However, the effects of lupeol on other melanoma such as canine melanoma remain unclear. In the present study, we examined the differentiation-inducing activities of lupeol on canine melanoma cells in vitro and its anti-melanoma effects in vivo, prior to clinical trials on canine melanoma.
Material and methods
With prior written informed consents of animal owners, 4 melanoma samples were separately harvested after surgical procedures, and 4 canine oral malignant melanoma (cMEL) cell lines were established from these tumor samples. The three melanoma cell lines (cMEL-1, -3, and -4) were maintained in Dulbecco’s modified Eagle’s medium, and cMEL-2 cells were maintained in RPMI-1640 medium, respectively, supplemented with 10% fetal calf serum, 100 μg/ml of streptomycin, and 100 U of penicillin.
Effect of lupeol on canine melanoma cell growth
Aliquots of 1 ml of cMEL-1-4 cells (1 × 104 cells) were incubated with various concentrations of lupeol (Sigma-Aldrich, INC.) for 4 days, and the number of viable cells was counted by trypan blue exclusion method. IC50 values, representing the concentration that inhibited melanoma cell growth by 50%, were measured.
RNA extraction and cDNA synthesis
Canine melanoma cells (2 × 104 cells) in 10 cm-dishes (10 ml) were incubated with or without lupeol for 2 days. Total RNA was isolated using the QuickGene RNA cultured cell kit S (FUJIFILM, Co.). Template cDNA synthesis was performed with 5 μg of total RNA using the PrimeScript RT Reagent Kit (TAKARA BIO, INC.)
Oligonucleotide primers used in real-time RT-PCR
Primer sequence (5'-3')
Subcutaneously administration of lupeol to canine melanoma-bearing mice
C.B-17/Icr-scid/scid Jc severe combined immunodeficiency (SCID) mouse were obtained from Crea Japan, INC.. A total of 1×107 cMEL-2 cells were subcutaneously injected into the back regions of SCID mice. Mice whose tumors grew to 10 mm in size were used in this study (day 0). Fifteen mice were randomized into 3 groups on day 0 (n = 5/group). Tumors were removed from 5 mice on day 0 and their weights were measured (day 0 group). Single injections of olive oil (0.1 ml, vehicle control group) or 0.5 mg lupeol in 0.1 ml olive oil (lupeol group) were subcutaneously administered around tumor tissue of each mouse at day 0. The tumor tissues of each mouse were removed 10 days after the injections, and their weights were measured. The experimental plan of the study was approved by the Ethics Committee for Animal Experimentation of Azabu University.
Results and discussion
We investigated whether lupeol induced the differentiation of canine oral malignant melanoma (cMEL) cells by evaluating some differentiation markers with real-time RT-PCR. Figure 1 shows the effects of 5 μM lupeol on the gene expression of microphthalmia-associated transcription factor (MITF), tyrosinase (TYR), and tyrosinase-related protein-2 (TRP-2) in 4 canine melanoma cells. Lupeol up-regulated MITF genes 1.5-3.1-fold, TYR genes 1.8-5.7-fold, and TRP-2 genes 1.9-3.9-fold, respectively, which indicated that the agent induced the differentiation of canine melanoma cells as well as mouse melanoma cells.
The proliferation of 4 canine melanoma cells was markedly suppressed by 10 μM lupeol, and this agent exhibited particularly strong anti-proliferative effects on cMEL-1 and -2 cells (Figure 2). The IC50 values of lupeol against 4 melanoma cells were 5.6 μM (cMEL-1), 2.3 μM (cMEL-2), 15.7 μM (cMEL-3), and 15.7 μM (cMEL-4), respectively; however, even at each IC50, all melanoma cells did not detach and remained >95% viable, suggesting that the inhibition of cell growth by lupeol can be attributed to its cytostatic (differentiation-inducing), but not cytotoxic effects.
PCNA is a cell-cycle regulator expressed in the nucleus of proliferating cells. The degree of PCNA expression has been correlated with tumor progression and grade in some tumors (Zeng and Davis 2003; Hall et al. 1990; Malham et al. 2010). Ki67 is also a cell proliferation marker, and the expression of Ki67 in the numerous melanoma tissues has been correlated with the presence of malignancy and prognosis (Gould Rothberg et al. 2009). We previously reported that lupeol suppressed the expression of PCNA and Ki67 in B16 mouse melanoma cells both in vitro and vivo. Therefore, we studied the effects of lupeol at each IC50 value against canine melanoma cell growth on the expression of PCNA and Ki67 genes. Real-time RT-PCR analysis revealed that lupeol suppressed the expression of PCNA and Ki67 in 4 canine melanoma cells by 47.4-68.0% and 43.4-62.5%, respectively (Figure 3).
Furthermore, we transplanted cMEL-2 cells into a SCID mouse, and studied the anti-progressive effects of lupeol on tumor tissue (Figure 4). Although the melanoma was 5.7-fold bigger by day 10, growth was significantly suppressed by 78.7% that of the vehicle control with the single administration of lupeol (p < 0.01). We administered lupeol to melanoma-bearing mice only once in the present study, and a higher dose and/or repeated injection of lupeol appeared to be more effective in treating the melanoma.
We demonstrated the differentiation-inducing and anti-proliferative activities of lupeol on 4 canine melanoma cells both in vitro and in vivo. We intend to establish a nonsurgical treatment for canine melanoma with lupeol based on these results.
This research was supported in part by the grant program “Enhancement Project of Intellectual Creation Cycle for Akita Prefectural Research Institutes”.
- Bergman PJ: Canine oral melanoma. Clin Tech Small Anim Pract 2007, 22: 55-60. 10.1053/j.ctsap.2007.03.004View ArticleGoogle Scholar
- Fernández MA, de Las Heras B, García MD, Sáenz MT, Villar A: New insights into the mechanism of action of the anti-inflammatory triterpene lupeol. J Pharm Pharmacol 2001a, 53: 1533-1539. 10.1211/0022357011777909View ArticleGoogle Scholar
- Fernández A, Alvarez A, García MD, Sáenz MT: Anti-inflammatory effect of Pimenta racemosa var. ozua and isolation of the triterpene lupeol. Farmaco 2001, 56: 335-338. 10.1016/S0014-827X(01)01080-1View ArticleGoogle Scholar
- Gould Rothberg BE, Bracken MB, Rimm DL: Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2009, 101: 452-474. 10.1093/jnci/djp038View ArticleGoogle Scholar
- Hall PA, Levision DA, Woods LA: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990, 162: 285-294. 10.1002/path.1711620403View ArticleGoogle Scholar
- Hata K, Mukaiyama T, Tsujimura N, Sato Y, Kosaka Y, Sakamoto K, Hori K: Differentiation-inducing activity of lupane triterpenes on a mouse melanoma cell line. Cytotechnology 2006, 52: 151-158.View ArticleGoogle Scholar
- Hata K, Hiwatashi K, Itoh M, Suzuki N, Watanabe T, Takahashi J, Sasaki H: Inhibitory effects of lupeol on 3 T3-L1 preadipocyte differentiation. Phytochem Lett 2008, 1: 191-193. 10.1016/j.phytol.2008.09.007View ArticleGoogle Scholar
- Itoh M, Hiwatashi K, Abe Y, Kimura F, Toshima G, Takahashi J, Sasaki H, Hata K: Lupeol reduces triglyceride and cholesterol synthesis in human hepatoma cells. Phytochem Lett 2009, 2: 176-178. 10.1016/j.phytol.2009.06.001View ArticleGoogle Scholar
- Malham P, Husain N, Bhalla S, Gupta RK, Husain M: Proliferating cell nuclear antigen, p53 and micro vessel density: grade II vs. Grade III astrocytoma Indian J Pathol Microbiol 2010, 53: 20-23. 10.4103/0377-4929.59177View ArticleGoogle Scholar
- Nitta M, Azuma K, Hata K, Takahashi S, Ogiwara K, Tsuka T, Imagawa T, Yokoe I, Osaki T, Minami S, Okamoto Y: Systemic and local injections of lupeol inhibit tumor growth in a melanoma-bearing mouse model. Biomedical Reports 2013, 1: 641-645.Google Scholar
- Oliveria S, Dusza S, Berwick M: Issues in the epidemiology of melanoma. Expert Rev Anticancer Ther 2001, 1: 453-459. 10.1586/1473722.214.171.1243View ArticleGoogle Scholar
- Rassnick KM, Ruslander DM, Cotter SM, Al-Sarraf R, Bruyette DS, Gamblin RM, Meleo KA, Moore AS: Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989–2000). J Am Vet Med Assoc 2001, 218: 1444-1448. 10.2460/javma.2001.218.1444View ArticleGoogle Scholar
- Saleem M: Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpenes. Cancer Lett 2009, 28(285):109-115.View ArticleGoogle Scholar
- Sasaki H, Kawarasaki S, Sugawara M, Hata K: Effects of lupeol on visceral fat weights and serum lipoprotein profiles in high-fat diet mice. J Clin Biochem Nutr 2008, 43(Suppl 1):422-424.Google Scholar
- Zeng H, Davis CD: Down-regulation of proliferating cell nuclear antigen gene expression occurs during cell cycle arrest induced by human fecal water in colonic HT-29 cells. J Nutr 2003, 133: 2682-2687.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.